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Microchimerism is defined as the presence of non-self and circulating cells in a host. The current study aimed to assess the effect 
of microchimerism on scleroderma major organ involvements.
This cross-sectional study was conducted on 56 scleroderma patients registered in a tertiary rheumatology center of Shiraz Univer-
sity of Medical Sciences. Information on the patients’ demographics and disease complications was gathered through a review of 
medical records. Skin score was applied to better assess skin thickening. High Resolution CT-scan as well as pulmonary function 
test (PFT) results were also used to investigate pulmonary involvement in patients. Y chromosome serum levels were measured 
using Phenol Chloroform Extraction protocol and following real-time PCR. 
Fifty-six scleroderma patients with a mean age of 46±10 years were recruited in this study (58.9% with diffuse scleroderma and 
41.07% with limited scleroderma). Other than skin thickening, the most common clinical presentation among the patients was 
interestitial lung disease (67.8%). No significant difference was found between Y chromosome levels of patients with either lung, 
cardiac, renal, or gastrointestinal involvement and those who did not have these complications. Y chromosome serum levels based 
on the results of PFT were also shown to have no significant difference. Moreover, no association was demonstrated between 
serum Y chromosome and skin score. 
The serum level of chromosome Y has no impact on the severity and frequency of major organ involvement in Iranian scleroderma 
patients. 
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Introduction 
Systemic sclerosis (Scleroderma, SSc) is an autoimmune 
disease characterized by collagen deposition in the skin 
and multiple internal organs [1, 2]. It has high incidence 
and prevalence in women of reproductive ages [2]. Study 
of the pathophysiology of this disease revealed that both 
genetic and environmental factors influence it. One recent-
ly proposed mechanism involved in the pathogenesis of 
SSc is microchimerism (Mc).
During pregnancy, the bidirectional flow of cells between 
mother and fetus occurs predominately from fetus to moth-
er [3]. Most of these cells go through apoptosis and de-
crease in number following parturition; however, a small 
number of them can still be detected in maternal blood and 
tissue even decades after childbirth. This is known as Mc 
[4, 5]. Whether or not these cells affect maternal health still 
remains open to question in the current literature (6, 7). 
Some studies have demonstrated the role of Mc in preg-
nancy complications, wound healing, and multiple malig-
nancies in mothers [3]. 
Recent research on the pathophysiology of autoimmune 
diseases, due to their female predominance, focused on the 
possible role of Mc in this group of disorders [1]. In previ-
ous studies, it was observed that women with scleroderma, 
rheumatoid arthritis, and Hashimoto’s thyroiditis had a 
higher frequency of Mc compared with the normal popula-
tion; consequently, it was concluded that this physiologic 
process can increase the risk of autoimmune diseases [8].
In their study on the association of Mc with clinical sub-
sets of scleroderma, Sahin et al. concluded that Mc can 
shorten the elapsed time of disease development in scle-
roderma patients; however, it was determined to have no 
association with clinical presentations of the disease [9].
On the other hand, another investigation into the effects 
of number of parities and gender of children on the epide-
miology and pathogenesis of scleroderma detected no sig-
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nificant association, which put into debate the suggested 
role of Mc in the pathogenesis of scleroderma [10]. 
The mentioned controversies between previous studies 
about the effect of Mc on the pathogenesis and clinical 
course of autoimmune diseases such as scleroderma man-
date further investigation on this topic. Moreover, due to 
the heterogeneity in prevalence and clinical presentations 
of SSc in different ethnicities and populations, it seems 
to be essential that more population-based studies be per-
formed. Therefore, the current study aimed to investigate 
the effect of Mc on major organ involvement of SSc, in-
cluding pulmonary, gastrointestinal, cardiac, and renal in-
volvement. 
Materials and Methods 
A cross-sectional study was done on 56 married female 
scleroderma patients registered in a tertiary rheumatology 
center of Shiraz University of Medical Sciences. The pa-
tients’ scleroderma was diagnosed based on LeRoy criteria 
[11].
Inclusion Criteria 
Married female scleroderma patients with ages between 
20-50 years were recruited in the present study. All pa-
tients had at least one male-gender child. 
Exclusion Criteria 
Patients with poor follow up or insufficient data in their 
medical records were excluded from the study. Patients 
with comorbid diseases such as diabetes, thyroid diseases, 
cardiovascular diseases, and hypertension, those who were 
cigarette smokers or opium addicts, and patients who had 
parietal complications including miscarriage, stillbirth, 
or death and those with twin siblings were also excluded 
from the study. 
Study Design 
A. Demographic data and disease clinical presenta-
tions: 
The patients’ demographic information and major clini-
cal presentations including skin, pulmonary, gastrointesti-
nal, cardiac, and renal involvement were reviewed using 
their medical records. 
To better assess skin thickening in patients, a skin score 
was estimated for each one [12]. Pulmonary involvement 
was also investigated using high-resolution computed to-
pography (HRCT) in addition to pulmonary function test 
(PFT). 
B. Determining quantitative measure of Y chromo-
some: 
A 3-ml blood sample was obtained from each patient 
by an expert technician into 10 cc BD Vacutainer EDTA 
tubes. Samples were then centrifuged at 3000 rpm for 10 
minutes at 4 °C and, approximately 1 cc of buffy coat was 
collected and stored at -80 °C for further processing. 
DNA molecules were extracted using the phenol-chloro-
form extraction protocol [13]. They were then mixed with 
master mix (Cybergreen, Takara, Japan, 2018) dye and 
underwent real time PCR (Step One Real-Time PCR Sys-
tem, USA, applied biosystems) to measure Y chromosome 
levels. 
Statistical Analysis 
Data was entered into Statistical Analysis (SPSS) 19 
software. Descriptive analysis was applied for reporting 
results on the prevalence of patients’ demographic infor-
mation and clinical presentations. The Mann-Whitney U 
test was also used to compare the Y chromosome levels 
between patients based on their major organ involvements. 
A p-value less than 0.05 was considered as statistically sig-
nificant.
Results 
Fifty-six married female scleroderma patients with a 
mean age at disease onset of 41±11 years and a mean age 
of 46±10 years at the beginning of the study were included 
in this study. Only 25% of participants had a positive fam-
ily history for rheumatologic diseases. About 58.9% and 
41.07% of patients had diffuse and limited scleroderma, 
respectively. The demographic information and disease 
characteristics of participants are summarized in Table 
1. The frequency of major organ involvement and clini-
cal presentations are apparent from Table 2, which shows 
that skin involvement is the most frequent presentation; 
consequently, sclerodactyly and Raynaud were detected in 
all participants. However, only 33.9% (19) of them had 
telangiectasia; 18 (32.1%) patients had pitting at the fin-
gertips, and 2 (3.57%) patients had calcinosis. Moreover, 
67.8% of participants had interstitial lung disease, and the 
most common symptom in patients with gastrointestinal 
involvement was dysphagia. Among 37 patients with gas-
trointestinal involvement, 9 (24.3%) of them had diarrhea, 
7 (18.9%) had constipation, 4 (10.8%) had vomiting, and 
3 (8.1%) patients had reflux. Four patients (0.07%) in the 
current study had kidney involvement, and 16 (28.5%) pa-
tients had cardiac involvement.
The serum levels of chromosome Y of patients were also 
compared based on the major clinical presentations, and 
the results are depicted in Table 3. The serum levels of 
chromosome Y were also compared with regard to the two 
major types of the disease, yet, no significant difference 
was found between patients with diffuse form (0.037 +- 
0.05) and those with limited scleroderma (0.078 + -0.17) 
(P value = 0.58).
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Table 1. Patients’ Demographic and Disease Characteristics
Patients’ Characteristics Results
Age of disease onset (mean±SD) 41± 11
Age at the time of study (mean±SD) 46±10
Disease Duration (mean±SD) 4± 5 
Positive family history of rheumatologic diseases (%(NO./TOTAL NO.)) 25 (14/56)
Type of disease (%(NO./TOTAL NO.))
1. Diffused 58.9(33/56)
2. Limited 41.07(23/56)
Table 2. Summery of patient’s clinical presentations
Patients Major Clinical Presentations %)NO./TOTAL NO.(
Interstitial Lung Disease 67.8(38/56)
Gastrointestinal Involvement 66.07 (37/56)
1. Dysphagia 45.9 ( 17/37)
2. Reflux 8.10 (3/37) 
3. Diarrhea 24.3 (9/37)
4. Constipation 18.9 (7/37)
5. Vomiting 10.8 ( 4/37)
Skin Involvement 100 ( 56/56)
1. Sclerodactyly 100 ( 56/56) 
2. Raynaud 100 (56/56)
3. Telangiectasia 33.9 (19/56)
4. Calcinosis 3.57 (2/56)
5. Digital Ulcer 50 ( 28/56)
6. Pitting at fingertips 32.1 (18/56)
Renal Involvement 0.07(4/56)
Cardiac Involvement 28.5(16/56)
Table 3. Comparing level of chromosome Y between patients regarding to their major clinical presentations.
Organ Involvement 
Chromosome Y level )mean ± SD ( 
P value 
Patients with organ involvement Patients without organ involvement 
Lung Involvement  (ILD) 0.06±0.14 0.03±0.07 0.86
Cardiac Involvement 0.09±0.2 0.03±0.06 0.33
Gastrointestinal involvement 0.03±0.07 0.08±0.1 0.18
Renal Involvement 0.05±0.1 0.05±0.1 0.85
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No association was found between disease duration 
and skin score (14.3±6.9) and Y chromosome levels 
(0.054±0.12)(p=0.999).
Analysis showed that there was no significant association 
between lung involvement (ILD) and Y chromosome level 
(P value=0.86), and no significant correlation was found 
between cardiovascular, gastrointestinal, or renal involve-
ment and Y chromosome levels.
According to the PFT results, 42.9% (24/56) had nor-
mal PFT and 42.9% (24/56) had restrictive lung disease. 
Comparing the Y chromosome levels between patients 
with restrictive lung disease results and those with normal 
PFT also showed no significant difference (normal PFT: 
0.05±0.1; restrictive lung disease: 0.39±0.05; P value = 
0.31). 
Furthermore, the mean skin score in patients of this study 
was estimated to be 14.3 ± 6.9. No significant association 
was found between the level of Y chromosome and skin 
score in patients of this study (P value = 0.96). 
Figure 1. Comparing the serum level of chromosome Y between diffused and limited type of scleroderma.
Discussion 
Scleroderma, like most other autoimmune diseases, has 
a strong predilection for women with a mean age of 45-
54 years [14]. Other epidemiologic studies on scleroderma 
have also declared that the peak incidence of this disease 
in women is following childbearing age [15]. The mean 
age of patients in the current study was 46±10 years at the 
time of the study, and at disease onset, it was 41±11 years. 
Microchimerism, as a physiologic finding in women fol-
lowing their pregnancies, was previously determined to 
have a role in the pathogenesis of autoimmune diseases, 
especially systemic sclerosis [15, 16]. Some previous quan-
titative studies detected that the level of Mc was signifi-
cantly higher in scleroderma women compared to normal 
healthy individuals [2]. Another study investigated a pos-
sible association between Mc and the limited form of SSc 
in addition to pulmonary fibrosis [17]. Some other studies 
have also supported the hypothesis on the role of Mc in 
the pathogenesis and organ involvement of SSc. A study 
by Johnson et al. on female scleroderma patients with at 
least one son detected that fetal cells can migrate form pe-
ripheral circulation into multiple organs. They suggested 
that it could support the role of Mc in the pathogenesis of 
SSc [18]. 
The current results revealed no significant difference in 
Y chromosome levels between scleroderma patients with 
either lung, cardiac, gastrointestinal, or renal involvement 
and ones without these complications. Moreover, using 
PFT, it was also determined that quantitative measures 
of Y chromosome do not differ between patients with re-
strictive patterns and ones with normal results. In addition, 
Y chromosome level was not associated with mean skin 
score, which was applied for assessing the severity of skin 
involvement in patients of the current study. No signifi-
LimitedDiffused
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cant difference was found between the two major types of 
the disease. These findings, unlike most previous surveys, 
brought under question the role of Mc in the pathogenesis 
of scleroderma. 
Some other studies can also be found which supported 
the current findings. A survey done on the effects of parity, 
family size, and gender of the children with the epidemi-
ology and pathogenesis of scleroderma found no signifi-
cant relationship [10]. Moreover, in evaluating the effect of 
prior pregnancies on scleroderma complications and death 
etiologies, it was manifested that nulliparous patients had 
earlier onset of the disease, more severe lung involvement, 
and a higher rate of death compared to multiparous ones 
[19]. 
These controversies regarding the role of Mc in the 
pathogenesis and clinical manifestations of scleroderma 
may be attributed to genetic variations between different 
ethnicities and cultures. In addition, the interval between 
the last pregnancy to lead to a son born in patients and the 
onset of their disease can also be another possible factor 
which may explain the differences between previous stud-
ies on the role of Mc in scleroderma. Nevertheless, further 
studies are needed to investigate these hypotheses. 
The current study can be introduced as the first study to 
assess the effect of Mc on the frequency and severity of 
major clinical manifestations in Iranian scleroderma pa-
tients. However, it has also some limitations. One limita-
tion of this study was its small sample size, which was 
inevitable due to the rarity of the disease and the presence 
of few female patients having a son. Furthermore, missing 
data, especially in patients’ medical records, was anoth-
er limitation which contributed to the small sample size. 
Nonetheless, efforts were made to minimize the amount of 
missing data on patients’ clinical presentations by adding 
confirmatory tests such as HRCT, PFT, and skin score. 
Conclusion 
Unlike previous literature, it was concluded that the se-
rum level of chromosome Y has no association with the 
severity and frequency of major organ involvement in 
Iranian scleroderma patients. This finding emphasized the 
possible role of genetic and ethnical variations in disease 
presentations, which mandates further regional investiga-
tions.
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